论文部分内容阅读
目的观察含羟基喜树硷(HCPT)联合化疗方案治疗晚期卵巢癌的近期疗效及不良反应。方法 29例,HCPT6mg/m2,静脉滴注,1～5月,醛氢叶酸100mg/m2。静脉滴注第1～5月;1-氟脲嘧啶400mg/m2,静滴第1～5月,顺铂(DDP)40mg,第1～3天,DDP应水化;7例因胃肠道反应未用DDP外余同上,3～4周为一个周期。结果 36例中总有效率(CR+PR)为50%(18/36)主要不良反应为血液学毒性,及恶心呕吐等。结论含羟基喜树硷的CFH/CFHP方案是治疗晚期卵巢癌有效且毒性较小的化疗方案
Objective To observe the short-term effects and side effects of HCPT combined with chemotherapy in the treatment of advanced ovarian cancer. Methods 29 cases, HCPT6mg / m2, intravenous drip, 1-5 months, 100mg / m2 of dihydrofolate. Intravenous infusion of 1 to 5 months; 1-fluorouracil 400mg / m2, intravenous drip from January to May, cisplatin (DDP) 40mg, 1 to 3 days, DDP should hydration; 7 cases of gastrointestinal The reaction did not use DDP as above, 3 to 4 weeks for a cycle. Results The total effective rate (CR + PR) in 36 cases was 50% (18/36) The main adverse reactions were hematologic toxicity, nausea and vomiting. Conclusions Hydroxycamptothecin-based CFH / CFHP regimen is an effective and less toxic chemotherapy regimen for advanced ovarian cancer